In addition, AAS have virilizing effects, which obviously is not an issue in men but has great clinical significance in women. These women tend to perform shorter cycles, favor other AAS types (stanozolol, oxandrolone) and use lower dosages. This is especially worrisome as there is considerable evidence that myocardial injury, which may accumulate in years of ongoing AAS use, is a primary cause for sudden cardiac death in AAS users (217). Consequently, an argument could be made to perceive these AAS-induced cardiac changes as risk modifiers when estimating CVD risk using algorithms such as SCORE2 or PCE, and could aid in ‘grey zone’ risk estimation situations. However, this does not preclude the possibility that these changes might become permanent with more prolonged AAS use or with repeated cycles that provide too little time for recovery to take place in between. Main findings included a substantial impairment of LV systolic function in the AAS group compared with the nonusers as evidenced by an 11%-point lower LV ejection fraction (LVEF) and impaired longitudinal 4-chamber strain (+4.6). The same study found that individuals using AAS for non-medical purposes had a higher employment rate and a higher household income than the general population. Since the discovery and synthesis of testosterone in the 1930s, AAS have been used by physicians for many purposes, with varying degrees of success. In countries where AAS are controlled substances, there is often a black market in which smuggled, clandestinely manufactured or even counterfeit drugs are sold to users. The term "anabolic steroid" is essentially synonymous with "steroidal androgen" or "steroidal androgen receptor agonist". The anabolic steroid, stanozolol, is used therapeutically to treat a number of pathological conditions and its clinical effects suggest that it can modulate connective tissue breakdown. In one study, stretched clitoral length increased from 1.4 cm at baseline to 3 cm after 4 months of receiving 200 mg testosterone cypionate every other week (226). One might extrapolate the effects of supraphysiological androgen levels from men to women with regard to blood pressure, erythrocytosis, lipid profile and cardiac structure. As such, the distinction between the terms anabolic steroid and androgen is questionable, and this is the basis for the revised and more recent term anabolic–androgenic steroid (AAS). (Likewise, all "androgens" are inherently anabolic.) Indeed, it is likely impossible to fully dissociate anabolic effects from androgenic effects, as both types of effects are mediated by the same signaling receptor, the AR. With these developments, anabolic steroid became the preferred term to refer to such steroids (over "androgen"), and entered widespread use. It was the first steroid with a marked and favorable separation of anabolic and androgenic effect to be discovered, and has accordingly been described as the "first anabolic steroid". Subsequently, in 1955, it was re-examined for testosterone-like activity in animals and was found to have similar anabolic activity to testosterone, but only one-sixteenth of its androgenic potency. In 1953, a testosterone-derived steroid known as norethandrolone (17α-ethyl-19-nortestosterone) was synthesized at G. Ziegler's work resulted in the production of metandienone, which Ciba Pharmaceuticals marketed as Dianabol. A number of the drugs have common metabolic pathways, and their excretion profiles may overlap those of the endogenous steroids, making interpretation of testing results a very significant challenge to the analytical chemist. Some AAS that are or can be 5α-reduced, including testosterone, DHT, stanozolol, and methyltestosterone, among many others, can or may modulate the GABAA receptor, and this may contribute as an alternative or additional mechanism to their central nervous system effects in terms of mood, anxiety, aggression, and sex drive. In contrast, AAS that are 4,5α-reduced, and some other AAS (e.g., 11β-methylated 19-nortestosterone derivatives), have no risk of gynecomastia. AAS were added to Schedule III of the candy96.fun Controlled Substances Act in the Anabolic Steroids Control Act of 1990. In Canada, researchers have concluded that steroid use among student athletes is extremely widespread. Besides AAS, Handelsman has criticized the term "selective androgen receptor modulator (SARM)" and claims about these agents as well. Relatedly, Handelsman exclusively uses the term "androgen" to refer to these agents in his publications. The group of 86 men could be further subdivided into those using AAS at the time of the study and those who were not. Although a few measurements (such as left posterior wall and interventricular septum thickness) were significantly different in the bodybuilders compared with controls, no significant differences were found between both groups of bodybuilders. For example, the first clinical trial examining the effects of AAS use on the heart was published in 1985 (214). The association between cardiomyopathy and AAS use has long been controversial (213) as a result of mixed study findings, mainly due to small sample sizes, weak study design and insensitive measurements of older echocardiographic techniques. Anabol is a sedating antihistamine with antimuscarinic, serotonin antagonist and Ca channel blocking properties. Large case-control studies are warranted to obtain sufficiently good quality data to provide better insights herein, as it is both virtually infeasible and morally unacceptable to investigate the long-term effects of AAS use in randomized controlled trials. Many of the short-term health effects are now well characterized, although the true long-term impact on well-defined clinical endpoints such as cardiovascular morbidity and mortality remains elusive. Side effects range from cosmetic issues such as acne vulgaris and clitoromegaly in women, to potentially life-threatening such as cardiovascular disease. Clitoral size was unaffected by a lower dosage of 25 mg testosterone enanthate weekly for 24 weeks in hysterectomized women (224).